Successful Dostarlimab Rechallenge Following Pembrolizumab‐Induced Autoimmune Hemolytic Anemia: A Case Report

ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering durable responses across multiple malignancies. However, these agents can trigger severe immune‐related adverse events (irAEs), including drug‐induced autoimmune hemolytic anemia (AIHA), which often necessita...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Zaid Khamis, Kai Wang, Mohammad Aldalahmeh, Salim Barakat, Nawaraj Adhikari, Raghad Khassawneh, Bhavya Misri, Dhar Meekoo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wiley 2025-08-01
Saila:Clinical Case Reports
Gaiak:
adverse immune events
autoimmune hemolytic anemia
checkpoint inhibitor rechallenge
dostarlimab
immune checkpoint inhibitors
pembrolizumab
Sarrera elektronikoa:https://doi.org/10.1002/ccr3.70776
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak